Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 575

1.

A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list.

Vitale A, Volk ML, De Feo TM, Burra P, Frigo AC, Ramirez Morales R, De Carlis L, Belli L, Colledan M, Fagiuoli S, Rossi G, Andorno E, Baccarani U, Regalia E, Vivarelli M, Donataccio M, Cillo U; Liver Transplantation North Italy Transplant program (NITp) working group.

J Hepatol. 2014 Feb;60(2):290-7. doi: 10.1016/j.jhep.2013.10.010. Epub 2013 Oct 23. Erratum in: J Hepatol. 2014 Jun;60(6):1336. Multiple investigator names added.

PMID:
24161408
2.

Waiting time predicts survival after liver transplantation for hepatocellular carcinoma: a cohort study using the United Network for Organ Sharing registry.

Schlansky B, Chen Y, Scott DL, Austin D, Naugler WE.

Liver Transpl. 2014 Sep;20(9):1045-56. doi: 10.1002/lt.23917. Epub 2014 Aug 4.

3.

Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era.

Berg CL, Merion RM, Shearon TH, Olthoff KM, Brown RS Jr, Baker TB, Everson GT, Hong JC, Terrault N, Hayashi PH, Fisher RA, Everhart JE.

Hepatology. 2011 Oct;54(4):1313-21. doi: 10.1002/hep.24494.

4.

MELDEQ : An alternative Model for End-Stage Liver Disease score for patients with hepatocellular carcinoma.

Marvin MR, Ferguson N, Cannon RM, Jones CM, Brock GN.

Liver Transpl. 2015 May;21(5):612-22. doi: 10.1002/lt.24098. Epub 2015 Apr 15.

5.
6.

Model for end-stage liver disease-sodium and survival benefit in liver transplantation.

Vitale A, Bertacco A, Gambato M, D'Amico F, Morales RR, Frigo AC, Zanus G, Burra P, Angeli P, Cillo U.

Transpl Int. 2013 Feb;26(2):138-44. doi: 10.1111/tri.12008. Epub 2012 Nov 29.

7.

Prospective validation of a new priority allocation model for liver transplant candidates: an interim analysis.

Vitale A, Saracino E, D'Amico FE, Grigoletto F, Burra P, Angeli P, Boccagni P, Brolese A, Zanus G, Neri D, Gringeri E, D'Amico F, Valmasoni M, Carraro A, Gambato M, Feltracco P, Romano A, Buggio M, D'Amico DF, Cillo U.

Transplant Proc. 2009 May;41(4):1092-5. doi: 10.1016/j.transproceed.2009.03.053.

PMID:
19460489
8.

Improved waiting-list outcomes in Argentina after the adoption of a model for end-stage liver disease-based liver allocation policy.

Cejas NG, Villamil FG, Lendoire JC, Tagliafichi V, Lopez A, Krogh DH, Soratti CA, Bisigniano L.

Liver Transpl. 2013 Jul;19(7):711-20. doi: 10.1002/lt.23665.

9.

Survival benefit after liver transplantation: a single European center experience.

Ravaioli M, Grazi GL, Dazzi A, Bertuzzo V, Ercolani G, Cescon M, Cucchetti A, Masetti M, Ramacciato G, Pinna AD.

Transplantation. 2009 Sep 27;88(6):826-34. doi: 10.1097/TP.0b013e3181b26807.

PMID:
19920783
10.

Comparison of Liver Transplant-Related Survival Benefit in Patients With Versus Without Hepatocellular Carcinoma in the United States.

Berry K, Ioannou GN.

Gastroenterology. 2015 Sep;149(3):669-80; quiz e15-6. doi: 10.1053/j.gastro.2015.05.025. Epub 2015 May 27.

PMID:
26021233
11.

A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list.

Toso C, Dupuis-Lozeron E, Majno P, Berney T, Kneteman NM, Perneger T, Morel P, Mentha G, Combescure C.

Hepatology. 2012 Jul;56(1):149-56. doi: 10.1002/hep.25603. Epub 2012 Jun 18.

PMID:
22271250
12.

The race to liver transplantation: a comparison of patients with and without hepatocellular carcinoma from listing to post-transplantation.

Patel MS, Kohn R, Kratz JR, Shah JA, Markmann JF, Vagefi PA.

J Am Coll Surg. 2015 Jun;220(6):1001-7. doi: 10.1016/j.jamcollsurg.2014.12.050. Epub 2015 Jan 21.

PMID:
25868408
13.

The MELD score in patients awaiting liver transplant: strengths and weaknesses.

Bernardi M, Gitto S, Biselli M.

J Hepatol. 2011 Jun;54(6):1297-306. doi: 10.1016/j.jhep.2010.11.008. Epub 2010 Nov 20.

14.

Survival Benefit of Liver Transplantation Versus Resection for Hepatocellular Carcinoma: Impact of MELD Score.

Vitale A, Huo TL, Cucchetti A, Lee YH, Volk M, Frigo AC, Cescon M, Tuci F, Pinna AD, Cillo U.

Ann Surg Oncol. 2015;22(6):1901-7. doi: 10.1245/s10434-014-4099-2. Epub 2014 Sep 19.

PMID:
25234023
15.

The impact of the model for end-stage liver disease (MELD) on liver transplantation in one center in Brazil.

Freitas AC, Itikawa WM, Kurogi AS, Stadnik LG, Parolin MB, Coelho JC.

Arq Gastroenterol. 2010 Jul-Sep;47(3):233-7.

16.

Waiting list mortality of patients with primary biliary cirrhosis in the Japanese transplant allocation system.

Genda T, Ichida T, Sakisaka S, Sata M, Tanaka E, Inui A, Egawa H, Umeshita K, Furukawa H, Kawasaki S, Inomata Y.

J Gastroenterol. 2014 Feb;49(2):324-31. doi: 10.1007/s00535-013-0782-5. Epub 2013 Mar 12.

PMID:
23478939
17.

Comparison of clinical outcomes in chronic hepatitis B liver transplant candidates with and without hepatocellular carcinoma.

Wong SN, Reddy KR, Keeffe EB, Han SH, Gaglio PJ, Perrillo RP, Tran TT, Pruett TL, Lok AS.

Liver Transpl. 2007 Mar;13(3):334-42.

18.

Impact of MELD score implementation on liver allocation: experience at a Brazilian center.

da Silva Machado AG, de Medeiros Fleck A Jr, Marroni C, Zanotelli ML, Cantisani G, de Mello Brandão AB.

Ann Hepatol. 2013 May-Jun;12(3):440-7.

19.

Excess mortality on the liver transplant waiting list: unintended policy consequences and Model for End-Stage Liver Disease (MELD) inflation.

Northup PG, Intagliata NM, Shah NL, Pelletier SJ, Berg CL, Argo CK.

Hepatology. 2015 Jan;61(1):285-91. doi: 10.1002/hep.27283. Epub 2014 Oct 29.

PMID:
24995689
20.

Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival.

Ioannou GN, Perkins JD, Carithers RL Jr.

Gastroenterology. 2008 May;134(5):1342-51. doi: 10.1053/j.gastro.2008.02.013. Epub 2008 Feb 13.

PMID:
18471511

Supplemental Content

Support Center